Building on a relationship struck last fall, Bavarian Nordic and Johnson & Johnson's Janssen unit inked a deal on Friday potentially worth $171 million plus milestones aimed at the development of a therapeutic HPV vaccine.
UPDATED: J&J; slapped with $1.75M verdict in Risperdal breast growth case
Johnson & Johnson lost another courtroom battle over claims that the company failed to warn doctors and patients that its antipsychotic drug Risperdal could cause breast growth in boys, a blow for the company as it continues to deal with related cases.
Injectable HIV regimen being developed by J&J; and ViiV Healthcare shows promise in trials
Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.
Janssen the latest Big Pharma to join Hanmi's South Korea deal machine
South Korea's Hanmi Pharmaceutical has licensed long-acting GLP/GCG analog diabetes and obesity candidate HM12525A to Janssen Pharmaceuticals, showcasing a deal making spree this year with major drug firms that includes two blockbusters this month alone.
J&J;'s Yondelis finally captures FDA nod, but path to big sales could be steep
Once upon a time, analysts thought the cancer-fighting prospect Yondelis could hit $1 billion in sales by 2010. But that timetable went poof years ago--and so did the forecast--as the drug failed to win the FDA's approval, and eventually ended up in a partnership between Spain's Zeltia and Johnson & Johnson's Janssen unit.
Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.
HIV activists join Janssen's story-focused Prezcobix effort
Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease.
Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest
Some heavy-hitting HIV activists have signed onto Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease. The Johnson & Johnson unit will award up to $20,000 in charitable donations as part of the effort, which ties in the company's latest HIV brand, Prezcobix.
Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.
Janssen's new Prezcobix push urges HIV patients to share pics with their docs
Say cheese, bus shelter ad. Janssen's Prezcobix campaign advocates a new way for potential patients to talk to their doctors: Snap a picture and share it.